Personalized Theranostics Research for Prostate Cancer

GE HealthCare and Mayo Clinic have established the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) research collaboration to investigate a personalized approach to radioligand therapy (RLT) for advanced prostate cancer. The study combines molecular imaging, blood-based biomarkers, and clinical outcome data to assess whether treatment decisions can be adapted according to an individual patient's response, supporting precision oncology and molecular imaging applications.

Background of the Collaboration
The collaboration builds on the Strategic Radiology Research Alliance established between GE HealthCare and Mayo Clinic in 2023. It addresses a key challenge in theranostics: although radioligand therapy enables targeted treatment of cancer using radiopharmaceuticals, treatment schedules are commonly based on a predefined number of therapy cycles rather than continuous assessment of individual disease response.

The project brings together Mayo Clinic's expertise in clinical research and oncology with GE HealthCare's molecular imaging technologies to evaluate whether imaging-derived biomarkers can support adaptive treatment strategies.

Technical Solution and Responsibilities
The MI-BET study uses GE HealthCare's StarGuide SPECT/CT imaging platform together with MIM Software's MIM LesionID Pro image analysis software. The imaging system provides quantitative SPECT/CT data throughout the treatment process, while lesion analysis software enables standardized assessment of tumor response.

Mayo Clinic leads the clinical study, patient management, data analysis, and evaluation of imaging findings alongside blood-based biomarkers and clinical outcomes. GE HealthCare provides imaging technology and technical expertise supporting image acquisition and quantitative assessment.

The study investigates whether integrated imaging and biomarker data can identify patients who may benefit from temporarily pausing radioligand therapy based on measured treatment response rather than fixed treatment schedules. Researchers will also evaluate potential predictive biomarkers capable of identifying treatment response at an early stage.

Deployment and Clinical Implementation
Research activities are conducted at Mayo Clinic's campus in Rochester, Minnesota. The collaboration also includes evaluation of GE HealthCare's next-generation StarGuide GX SPECT/CT system, investigating its potential to reduce scan duration while improving the precision of tumor assessment.

The imaging workflow is integrated into existing clinical practice, allowing repeated quantitative assessments during treatment without changing the overall therapeutic pathway.

Applications and Industrial Relevance
The study supports the development of adaptive treatment strategies for advanced prostate cancer within theranostics and precision oncology. Potential applications include individualized treatment planning, longitudinal monitoring of therapeutic response, biomarker validation, and data-driven clinical decision support.

If validated, these methods could improve treatment efficiency, reduce unnecessary therapy cycles, optimize utilization of radioligand therapy resources, and support broader implementation of personalized cancer treatment.

Results and Expected Impact
The collaboration aims to generate clinical evidence on the use of imaging biomarkers and quantitative molecular imaging for adaptive radioligand therapy. Although no clinical outcome data have been reported, the research is expected to improve understanding of patient-specific treatment response and support future development of predictive decision-support models for precision oncology.

Edited by Evgeny Churilov, Induportals Media - Adapted by AI.

www.gehealthcare.com